Skip to main content

Ken Kobayashi, M.D., F.A.C.P

Equibles does not estimate personal net worth.

Get an email with a short summary when Pyxis Oncology, Inc. publishes a filing, an earnings call transcript or a press release.

Get PYXS alerts

About Ken Kobayashi, M.D., F.A.C.P

Pyxis Oncology, Inc. reported in an 8-K filed March 18, 2025 that Ken Kobayashi, M.D., F.A.C.P resigned as Chief Medical Officer, effective March 18, 2025. The same filing states: “His resignation will be effective as of March 18, 2025 and is not associated with, or attributable to, any disagreement regarding any matter related to the Company's operations, policies or practices.” Pyxis Oncology, Inc. reported in an 8-K filed November 28, 2023 that Ken Kobayashi, M.D., F.A.C.P was appointed Chief Medical Officer, effective November 27, 2023. Pyxis Oncology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Pyxis Oncology, Inc. includes Thomas Civik (CEO, Chairman and Board Member), Pamela Connealy (COO), Jitendra Wadhane (Chief Accounting Officer) and 4 others.

“Ken Kobayashi, M.D., F.A.C.P, is stepping down from his position as the Company's Chief Medical Officer.”
“His resignation will be effective as of March 18, 2025 and is not associated with, or attributable to, any disagreement regarding any matter related to the Company's operations, policies or practices.”
Pyxis Oncology, Inc. Form 8-K, filed March 18, 2025 · Read the filing
“On November 28, 2023, Pyxis Oncology, Inc. (the "Company") announced the appointment of Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer, effective as of November 27, 2023 (the "Effective Date").”
Pyxis Oncology, Inc. Form 8-K, filed November 28, 2023 · Read the filing

Affiliation history

Company network

Leadership on record at Pyxis Oncology, Inc.

Recent activity